# Adamax

> Adamax is described in vendor and research-community literature as a synthetic analog related to the ACTH(4-10) fragment family that also includes Semax, proposed to share a similar anxiolytic and nootropic profile. Independent, peer-reviewed research specifically on Adamax is scarce, and much of what circulates about it draws by analogy from better-studied family members rather than from dedicated trials. It should be regarded as an emerging and largely uncharacterized research compound rather than an established one. It is not approved for medical use and is available only as a research compound.

- URL: https://www.lifeconverted.com/peptides/adamax
- Primary category: Cognitive & Neuro
- Effectiveness rank: #6 in Cognitive & Neuro
- Evidence level: Emerging research
- Route: Subcutaneous (Administered by subcutaneous injection in research contexts, consistent with related Semax-family peptides.)
- Dose range: 200-600 mcg
- Dose tiers: low 200 mcg; moderate 400 mcg; high 600 mcg
- Half-life: Dedicated human pharmacokinetic data are not available; by analogy to related peptides in this family, plasma half-life is presumed to be short.
- Timing: Morning
- Cycle: 4-6 weeks on, 2-4 weeks off (Cycling recommendations are extrapolated entirely from related, better-studied peptides rather than from dedicated research on Adamax.)
- Storage: Store lyophilized peptide refrigerated (2-8°C) or frozen prior to reconstitution, protected from light. After reconstitution, keep refrigerated and use within about 2-4 weeks.

## Mechanism of action

Adamax is proposed, by structural analogy to Semax, to influence central dopaminergic and serotonergic signaling and to support expression of neurotrophic factors such as BDNF. Because dedicated studies are lacking, this proposed mechanism is inferred rather than independently demonstrated for Adamax itself.

## Reported benefits

- Proposed nootropic and anxiolytic effects by analogy to related Semax-family peptides
- Discussed informally for supporting attention and stress resilience
- Considered within broader neuroprotective research frameworks
- May offer a non-sedating profile similar to related compounds

## Reported side effects

- Essentially no independent human safety data are available
- Injection site irritation with subcutaneous use
- Effects and risks are largely extrapolated rather than directly studied
- Unknown long-term safety profile

## Common protocols

- Daily dosing patterns modeled on protocols used for related Semax-family peptides, without dedicated supporting research

## Stacking notes

Sometimes discussed alongside Semax or other related peptides in informal research contexts; no controlled data exist on its use alone or in combination.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer